Infection protectant
October 26, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod of treating diarrhea employing a formaldehyde-modified casein Extraction of glycoproteins and sialic acid from whey Rennet casein and method for treatment thereof Total enzymatic hydrolysate from whey proteins and process of obtaining the same Biologically active substances, their obtainment from human casein and compositions containing said substances Phosphopeptides from casein-based material Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides Method of preventing or treating thrombosis using kappa-caseinoglycopeptide as active ingredient Patent #: 5063203 InventorsAssigneeApplicationNo. 604333 filed on 10/26/1990US Classes:514/7, Phosphorus containing435/41, MICRO-ORGANISM, TISSUE CELL CULTURE OR ENZYME USING PROCESS TO SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION435/68.1, Enzymatic production of a protein or polypeptide (e.g., enzymatic hydrolysis, etc.)514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/8, Glycoprotein (carbohydrate containing)514/21, Produced by or extracted from animal tissue530/322, Peptides containing saccharide radicals, e.g., bleomycins, etc.530/360, Casein or caseinate530/391.1, Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/409, Nitrogen containing reactant530/411Oxygen containing is saccharideExaminersPrimary: Nucker, Christine M.Assistant: Kim, Harry C. Attorney, Agent or FirmInternational ClassesA61K 037/16A61K 033/42 C07K 015/14 Foreign Application Priority Data1987-05-15 JPAbstractDisclosed herein is an infection protectant which is excellent in infection protective effects and is also safe. κ-Casein, a sialic-acid-conjugated protein derived from cow milk, and a glycomacropeptide derived from κ-casein, each of which is useful as an active ingredient in this invention, have been found to be effective for the prevention of adhesion of E. coli on cells and also for the inhibition of transformation of lymphocytes by EBV and also to have strong HI activity against virus. The infection protectant of this invention is hence believed to exhibit marked effects for the prevention of occurrence of infectious diarrhea, for mass protection against spreading of influenza, and also against canceration of lymphocytes. Since the active ingredient of the infection protectant is a substance derived from cow milk, it is free of any problem from the viewpoint of safety. Moreover, it is absolutely tasteless and odorless. It can therefore be added to foods for its application.Other References
Field of SearchPeptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAIGlycoprotein (carbohydrate containing) Produced by or extracted from animal tissue Phosphorus containing Peptides containing saccharide radicals, e.g., bleomycins, etc. Casein or caseinate Glycoprotein, e.g., mucins proteoglycans, etc. Nitrogen containing reactant Oxygen containing is saccharide MICRO-ORGANISM, TISSUE CELL CULTURE OR ENZYME USING PROCESS TO SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION Enzymatic production of a protein or polypeptide (e.g., enzymatic hydrolysis, etc.) |
| ||||||||||||||
